1. Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study.
- Author
-
Stephenson CM, Bigliani V, Jones HM, Mulligan RS, Acton PD, Visvikis D, Ell PJ, Kerwin RW, and Pilowsky LS
- Subjects
- Adult, Clozapine metabolism, Corpus Striatum diagnostic imaging, Female, Humans, Male, Middle Aged, Quetiapine Fumarate, Receptors, Dopamine D3, Temporal Lobe diagnostic imaging, Temporal Lobe metabolism, Tomography, Emission-Computed, Single-Photon, Antipsychotic Agents metabolism, Benzamides, Corpus Striatum metabolism, Dibenzothiazepines metabolism, Iodine Radioisotopes, Pyrrolidines, Receptors, Dopamine D2 metabolism
- Abstract
Background: Selective action at limbic cortical dopamine D(2)-like receptors could mediate atypical antipsychotic efficacy with few extrapyramidal side-effects., Aims: To test the hypothesis that quetiapine has 'limbic selective' D(2)/D(3) receptor occupancy in vivo., Method: The high-affinity D(2)/D(3) ligand [(123)I]-epidepride and single photon emission tomography were used to estimate D(2)/D(3) specific binding and an index of relative percentage D(2)/D(3) occupancy in striatal and temporal cortical regions for quetiapine-treated patients (n=6). Quetiapine-, and previously studied typical-antipsychotic- and clozapine-treated patients were compared., Results: Mean (s.d.) relative percentage D(2)/D(3) receptor occupancy by quetiapine was 32.0% (14.6) in striatum and 60.1% (17.2) in temporal cortex (mean daily dose 450 mg: range 300-700 mg/day). Quetiapine treatment resulted in limbic selective D(2)/D(3) blockade similar to clozapine and significantly higher than typical antipsychotics., Conclusions: Preliminary data suggest that limbic selective D(2)/D(3) receptor blockade is important for atypical drug action.
- Published
- 2000
- Full Text
- View/download PDF